Is erythropoietin an acceptable treatment modality for routine use in preventing anaemia of prematurity?

Autor:	Medha Weerasekara, S I Samarasekara
Rok vydání:	2011
Předmět:	Pediatrics medicine.medical_specialty business.industry Enteral feedings Treatment period Child health Folic acid Reticulocyte count Treatment modality Erythropoietin hemic and lymphatic diseases Pediatrics Perinatology and Child Health medicine Sri lanka business medicine.drug
Zdroj:	Sri Lanka Journal of Child Health. 40:159
ISSN:	2386-110X 1391-5452
DOI:	10.4038/sljch.v40i4.3841
Popis:	Objectives: To find out whether routine use of erythropoietin (EPO) would reduce transfusion requirements in infants Methods: Seventy eight infants were randomized. Cases received subcutaneous EPO 300 units/kg/day,thrice weekly starting before 72 hours of birth for 14 days. All infants were given oral iron and folic acid with initiation of enteral feedings and this was continued during the entire treatment period. Results: EPO treated group acquired high reticulocyte counts earlier than control group with maximal difference in 2nd week but there was no statistically significant difference between groups. There was a gradual decline in haemoglobin values in both cases and controls; though this was less marked in the EPO treated group, the difference was not statistically significant. There was no statistically significant difference in total transfusion requirements between infants who received EPO and the control group. Conclusion: There is no benefit from routine use of EPO during the first two weeks of life in preventing anaemia of prematurity. (Key words: Erythropoietin; EPO; anaemia of prematurity; haemoglobin; reticulocyte count) DOI: http://dx.doi.org/10.4038/sljch.v40i4.3841 Sri Lanka Journal of Child Health, 2011; 40(4): 159-163
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0bd8d8e58b9cf6f03992b376fb0d04e0 https://doi.org/10.4038/sljch.v40i4.3841 Zobrazit plný text záznamu